Indio (111in) Ossina

Indium-111 oxine, the active ingredient in Indio (111in) Ossina, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is employed to label white blood cells, enabling nuclear imaging of infection, inflammation and related conditions in adult and pediatric patients.

GNH USA supplies Indio (111in) Ossina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to EU GMP standards and provides regulatory support for cross‑border distribution, ensuring product integrity and timely delivery.

Indium-111 oxine is used in nuclear medicine to image infection and inflammatory processes.

- Acute infection: enables detection of bacterial infections by visualizing labeled leukocyte accumulation. - Chronic osteomyelitis: assists in localizing bone infection for surgical planning. - Prosthetic joint infection: helps differentiate septic from aseptic loosening of implants. - Fever of unknown origin: supports identification of occult infectious foci.

Adverse reactions are generally related to the radiopharmaceutical nature of the product and the intravenous route.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Transient fever: short‑lived rise in body temperature. - Nausea: mild queasiness following administration. - Headache: occasional mild headache. - Flushing: brief skin reddening. - Mild hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: marked blood pressure decline needing intervention. - Radiation‑induced marrow suppression: rare decrease in blood cell production. - Severe allergic dermatitis: extensive skin reaction. - Acute renal impairment: rare kidney function decline. - Persistent infection at injection site: uncommon but serious local infection.

Careful assessment and monitoring are essential when using Indium-111 oxine. - Renal function: evaluate kidney performance as the tracer is renally excreted. - Pregnancy: avoid unless the diagnostic benefit outweighs fetal radiation risk. - Breastfeeding: discontinue nursing for an appropriate interval after administration. - Concurrent radiopharmaceuticals: avoid overlapping studies to prevent cumulative radiation exposure. - Allergy history: screen for hypersensitivity to indium or oxine compounds. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 oxine may interact with other agents that affect blood cells or radiation exposure.

Major Interactions (Avoid): - Chemotherapy agents: can increase marrow toxicity when combined. - Other radiopharmaceuticals: additive radiation dose may exceed safety limits. - High‑dose steroids: may reduce leukocyte labeling efficiency.

Moderate Interactions (Monitor Closely): - Iodinated contrast media: may interfere with imaging interpretation. - Anticoagulants: could alter leukocyte function and distribution. - Immunosuppressants: may affect the immune response and tracer uptake.